SOURCE: Entest BioMedical Inc

March 10, 2010 08:00 ET

Entest BioMedical Strengthens Its Research Capabilities by Adding Clinical Trials Expert Dr. Vladimir Bogin to Its Scientific Advisory Board

Dr. Bogin Is an Expert in Stem Cell Clinical Trials and the CEO of Cromos Pharma LLC; Company Sees Addition Aiding Clinical Trials Development for COPD Stem Cell Treatment Model

SAN DIEGO, CA--(Marketwire - March 10, 2010) - Entest BioMedical Inc. (OTCBB: ENTB) announced today the addition of Vladimir Bogin, M.D. to its scientific advisory board (SAB). Dr. Bogin is the CEO of Cromos Pharma LLC, a contract research organization (CRO) specializing in the development and operation of clinical trials. The Company feels the addition of Dr. Bogin to the SAB will greatly assist in developing its clinical protocols as it moves forward to conducting both pre-clinical and clinical trials of its Stem Cell / Photoceutical Treatment for Chronic Obstructive Pulmonary Disease (COPD).

One of the key areas in which Dr. Bogin will assist Entest will be the identification of end point measurements of the efficacy of its COPD Stem Cell treatment. Determining markers of success in treatment, along with meaningful thresholds of achievement are important in assessing the value of the Company's approach to its anticipated cure for COPD, which is the 4th leading cause of death in the United States.

Entest Chairman & CEO David Koos said, "We see the addition of Dr. Bogin to our SAB as a strong move in developing our research model going forward. His wealth of experience in designing and implementing clinical trials will guide us in targeting success in our research endeavors to cure this terrible disease."

Dr. Bogin holds a Medical Faculty appointment at Pharmatech, a research management organization linking both Clinical Research Organization and Site Management Organization services to pharmaceutical and biotech clients for the development and management of clinical research trials. He is a member of the Advisory Board at and the stem cell biotech company Orcrist Inc. Dr. Bogin has also held a Medical Faculty appointment at AdventRx Pharmaceuticals, and served as a Hospitalist in internal medicine at St. John Medical Center in Longview, WA, where he currently holds a Vice-Chairmanship in the Dept. of Medicine.

About Entest BioMedical Inc.:

Entest BioMedical Inc. (OTCBB: ENTB) is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), immuno-cancer therapies, testing procedures for diabetes, stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation). ENT - 576™ is a proprietary laser device currently under development by Entest. The Company has filed 3 patent applications relating to the treatment of COPD. Entest Biomedical Inc. is a majority owned subsidiary of Bio-Matrix Scientific Group Inc. (OTCBB: BMSN). Recently Entest published in the peer reviewed literature its platform technology, which is available at

About Bio-Matrix Scientific Group:

Bio-Matrix Scientific Group Inc. (OTCBB: BMSN) is a biotechnology company headquartered in San Diego, Ca. with a 15,000 sq. ft. facility that houses two secure cryogenic stem cell banks, three research laboratories, aseptic cellular/tissue class 10,000/100 processing lab, hematology, microbiology and flow cytometry laboratories. David Koos serves as Chairman & CEO concurrently for BMSN and ENTB.

Forward-looking statements:

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Follow the Company's progress on Twitter:

Contact Information